F m Investments LLC Has $8.85 Million Stock Position in Medtronic PLC $MDT

F m Investments LLC reduced its position in shares of Medtronic PLC (NYSE:MDT) by 4.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 101,502 shares of the medical technology company’s stock after selling 4,891 shares during the quarter. F m Investments LLC’s holdings in Medtronic were worth $8,848,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of MDT. Norges Bank bought a new stake in shares of Medtronic during the 2nd quarter valued at $1,432,698,000. Boston Partners grew its position in shares of Medtronic by 122.8% in the 1st quarter. Boston Partners now owns 6,912,055 shares of the medical technology company’s stock valued at $619,460,000 after purchasing an additional 3,809,450 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Medtronic by 28.8% during the first quarter. Ameriprise Financial Inc. now owns 15,481,028 shares of the medical technology company’s stock worth $1,391,141,000 after acquiring an additional 3,461,221 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Medtronic by 42.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,059,135 shares of the medical technology company’s stock valued at $903,915,000 after purchasing an additional 3,017,849 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Medtronic during the 1st quarter worth approximately $260,649,000. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on MDT shares. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the company an “outperform” rating in a report on Wednesday, November 19th. Robert W. Baird raised their target price on shares of Medtronic from $103.00 to $109.00 and gave the company a “neutral” rating in a research report on Wednesday, November 19th. UBS Group boosted their price target on shares of Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Barclays raised their price objective on Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, November 20th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $109.72.

Insider Activity

In related news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $105.13 on Friday. The business’s 50 day moving average price is $95.87 and its two-hundred day moving average price is $91.48. The company has a market cap of $134.85 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the firm posted $1.26 earnings per share. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.